Yung-Ping Yeh - Mar 30, 2021 Form 4/A - Amendment Insider Report for Vyant Bio, Inc. (VYNT)

Role: Chief Innovation Officer, Director
Signature: /s/ Andrew LaFrence, attorney-in-fact
Stock symbol: VYNT
Transactions as of: Mar 30, 2021
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 7/13/2021, 09:00 AM
Date Of Original Report: Apr 1, 2021
Next filing: May 21, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYNT	Common Stock, $0.0001 par value	Other		+11.3K			11.3K	Mar 30, 2021	Direct	F1
transaction	VYNT	Common Stock, $0.0001 par value	Other		+1.32M			1.32M	Mar 30, 2021	By Trust	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This amended Form 4 is being filed to correct (i) the number of shares of common stock $0.0001 par value (the "Common Stock") issued pursuant to the merger on March 30, 2021 and (ii) the disclosure of shares previously reported as owned directly that were transferred to a trust prior to the merger.

Remarks:

(1) Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's Common Stock in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.